HC Wainwright & Co. reiterated coverage on Balchem with a new price target
$BCPC
Major Chemicals
Industrials
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $170.00 → $155.00 | Buy | HC Wainwright & Co. |
| 2/22/2022 | $175.00 | Neutral → Buy | Sidoti |
| 1/10/2022 | $160.00 → $170.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $175.00 | Buy → Neutral | Sidoti |
| 8/2/2021 | $140.00 → $145.00 | Overweight → Equal-Weight | Stephens & Co. |
| 8/2/2021 | $145.00 → $160.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $155.00 from $170.00 previously
Sidoti upgraded Balchem from Neutral to Buy and set a new price target of $175.00
HC Wainwright & Co. reiterated coverage of Balchem with a rating of Buy and set a new price target of $170.00 from $160.00 previously
SCHEDULE 13G/A - BALCHEM CORP (0000009326) (Subject)
DEFA14A - BALCHEM CORP (0000009326) (Filer)
DEF 14A - BALCHEM CORP (0000009326) (Filer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
4/A - BALCHEM CORP (0000009326) (Issuer)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
SC 13G/A - BALCHEM CORP (0000009326) (Subject)
MONTVALE, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at the Wells Fargo Industrials and Materials Conference on June 11, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations will present at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the fi
MONTVALE, N.J., May 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the dbAccess Global Consumer Conference on June 4, 2025. Ted Harris, Chairman of the Board, Chief Executive Officer, and President and Martin Bengtsson, Chief Financial Officer will participate at the conference. About Balchem Corporation Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet, providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The
MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o
MONTVALE, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2025 fiscal first quarter ended March 31, 2025. For the quarter, the Company reported net sales of $250.5 million, net earnings of $37.1 million, adjusted EBITDA(a) of $66.3 million, and free cash flow(a) of $31.0 million. Ted Harris, Chairman, President and CEO of Balchem said, "The first quarter was an excellent start to the year for Balchem, with sales and earnings growth in all three segments. We delivered record net sales and adjusted EBITDA, strong net earnings, and solid first quarter cash flows." First Quarter 2025 Financial Highlights: Record net sales o
MONTVALE, N.J., April 11, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) today announced that a conference call will be held on Thursday, April 24, 2025, at 11:00 AM Eastern Time (ET) to review first quarter 2025 results. Ted Harris, Chairman of the Board, President and CEO, and Martin Bengtsson, CFO, will host the call. First quarter results will be published prior to the market opening on Thursday, April 24, 2025. The press release, and its accompanying financial exhibits, will also be available on the Company website, www.balchem.com, prior to the conference call. We invite you to listen to the conference by calling toll-free 1-877-407-8289 (local dial-in 1-201-689-8341),
MONTVALE, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ:BCPC) reported today financial results for its 2024 fiscal fourth quarter ended December 31, 2024. For the quarter, the Company reported net sales of $240.0 million, net earnings of $33.6 million, adjusted EBITDA(a) of $62.8 million, and free cash flow(a) of $39.8 million. Ted Harris, Chairman, President, and CEO of Balchem said, "The fourth quarter capped off another very strong year for Balchem. We delivered record fourth quarter net sales and adjusted EBITDA, with top and bottom line year over year growth in each of our three segments." Fourth Quarter 2024 Financial Highlights:
BOCA RATON, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of Directors effective immediately. The appointment increases the size of AzurRx's Board to seven members. Ms. Coelho currently serves as the Executive Vice President and Chief Financial Officer at BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a commercial-stage specialty pharmaceutical company. During her more than 30-year career, Ms. Coelho has held numerous senior level financial an